Filing Flows › Gyre Therapeutics (GYRE) › Q3 2026
Gyre Therapeutics (GYRE) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
Gyre Therapeutics (GYRE) reported revenue of $32.9M for the third quarter 2026 (Q3 2026), +0.7% from a year earlier and +13% from the quarter before. Operating margin was -4.6%, net loss $2.5M (7.5% of revenue).
Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%, net loss $2.5M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32.9M | +13% | +0.7% |
| Operating profit | −$1.5M | — | -122% |
| Net earnings | −$2.5M | — | -142% |
| Operating cash flow | −$4.0M | — | -185% |
What changed
Revenue was $32.9M in Q3 2026, up 1% year over year and up 13% from the previous quarter. Gyre Pharmaceuticals was the largest line at 98% of revenue. Gyre Pharmaceuticals added $1.9M year over year (up 6%), 776% of the total change. Gyre declined 76%.
Operating costs exceeded revenue by $1.5M, an operating margin of -4.6%. The fastest-growing cost line was Other operating costs (+78%). The quarter ended with a net loss of $2.5M, narrower than the previous quarter's $23.0M loss.
Operating cash flow was −$4.0M. Non-cash charges added back $467K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $3.7M. Capital expenditures of $1.0M exceeded it, leaving free cash flow of −$5.0M.
Questions
What was Gyre Therapeutics' revenue in the third quarter 2026?
Gyre Therapeutics (GYRE) reported revenue of $32.9M for the third quarter 2026 (Q3 2026), +0.7% from a year earlier and +13% from the quarter before.
Was Gyre Therapeutics profitable in the third quarter 2026?
Operating loss was $1.5M (-4.6% of revenue) and net loss $2.5M.
Source: Gyre Therapeutics 10-Q on SEC EDGAR.